Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.
Giulia MauleAntonio CasiniClaudia MontagnaAnabela S RamalhoKris De BoeckZeger DebyserMarianne S CarlonGianluca PetrisAnna CeresetoPublished in: Nature communications (2019)
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CFTR gene. The 3272-26A>G and 3849+10kbC>T CFTR mutations alter the correct splicing of the CFTR gene, generating new acceptor and donor splice sites respectively. Here we develop a genome editing approach to permanently correct these genetic defects, using a single crRNA and the Acidaminococcus sp. BV3L6, AsCas12a. This genetic repair strategy is highly precise, showing very strong discrimination between the wild-type and mutant sequence and a complete absence of detectable off-targets. The efficacy of this gene correction strategy is verified in intestinal organoids and airway epithelial cells derived from CF patients carrying the 3272-26A>G or 3849+10kbC>T mutations, showing efficient repair and complete functional recovery of the CFTR channel. These results demonstrate that allele-specific genome editing with AsCas12a can correct aberrant CFTR splicing mutations, paving the way for a permanent splicing correction in genetic diseases.
Keyphrases
- cystic fibrosis
- genome editing
- crispr cas
- pseudomonas aeruginosa
- genome wide
- copy number
- lung function
- wild type
- end stage renal disease
- dna methylation
- newly diagnosed
- peritoneal dialysis
- chronic kidney disease
- gene expression
- genome wide identification
- inflammatory response
- chronic obstructive pulmonary disease
- lipopolysaccharide induced
- lps induced